Neurocognitive Trajectories After BCMA CAR-T

Starting soon

Conditions studied: Multiple Myeloma (MM), CART Therapy, Refractory Multiple Myeloma (RRMM)

In brief

The purpose of this research study is to evaluate cognitive changes over time in participants with relapsed or refractory multiple myeloma who have received chimeric antigen receptor T-cell therapy (CAR-T).

Key facts

Study ID

NCT07740317

Run by

Wake Forest University Health Sciences

People needed

50

Starts

2026-09-01

Expected to finish

2029-11-01

Last updated by the study team

2026-07-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ability to understand and willingness to sign an IRB-approved informed consent
• Ability to retain independent decision-making capacity as per the enrolling investigator
• Age ≥ 18 years of age at the time of consent
• Scheduled to receive BCMA CAR-T therapy for RRMM as confirmed by the treating clinician
• Ability to read and understand the English language
• ECOG 0-2
• If actively taking benzodiazepine, must be able to hold for 3 hours prior to study assessments as per treating clinician
• Reliable access to internet access; a tablet, laptop and/or desktop computer with a camera; or willingness to come into the clinic to conduct study procedures as outlined in the Study Calendar- as per participant self-report
• Ability to complete required assessments, as determined by the treating clinician

You may not qualify if…

• Active central nervous system (CNS) disease
• Known neurodegenerative disease or major neurocognitive disorder
• Stroke and/or traumatic brain injury (TBI) within 12 months
• Concurrent investigational neuroactive drugs

Where it is running

• Atrium Health Levine Cancer — Charlotte, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.